中医药调节肠道菌群对结直肠癌治疗的临床价值

结直肠癌(CRC)是世界范围内发病率和死亡率较高的的消化道恶性肿瘤,美国一项统计发现癌症死亡率2017年为止,总体下降29%,然而,在过去十年间(2008—2017年),结直肠癌的死亡率下降缓慢,发病率居第四位,死亡率居第三位。治疗上对于晚期结直肠癌,化疗已进入瓶颈,其毒副作用和耐药问题不能有效解决,基于此,如何有效防治结直肠癌细胞的侵袭、迁移是治疗结直肠癌的关键。文章通过论述肠道菌群在中医病因学中的作用机制,及中医中药改善肠道微生物菌群的构成比,肠道菌群参与宿主免疫调节等方面,探讨中医药通过调节肠道菌群直接或间接延缓结直肠癌的发生、发展,进而为中医学改善结直肠癌患者的预后提供思路。

Clinical Value of TCM in Treating CRC by Regulating Intestinal Microflora

Colorectal cancer(CRC)is a digestive tract malignant tumor with high morbidity and mortality worldwide.A statistics in the United States found that the overall cancer mortality rate decreased by 29%until 2017.However,in the past decade(2008-2017),the mortality rate of CRC declined slowly,ranking fourth in morbidity and third in mortality.For advanced CRC,chemotherapy has entered the bottleneck,and the problems of toxicity and drug resistance can not be solved effectively.Based on this,how to effectively prevent the invasion and migration of CRC cells is the key to the treatment of CRC.This study discussed that TCM can directly or indirectly delay the occurrence and development of CRC by regulating intestinal flora,in terms of the mechanism of intestinal microflora in etiology of TCM,the improvement of the constituent ratio of intestinal microflora and the participation of intestinal microflora in host immune regulation,so as to provide ideas for TCM in improving the prognosis of patients with CRC.